• Johnson & Johnson reported early Phase 1 results showing sustained reductions in a prostate cancer marker with investigational pasritamig plus JNJ-9401.
• Results were presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting.
• No severe treatment-related adverse events were reported at the recommended regimen in patients with metastatic castration-resistant prostate cancer.
• Findings involved a small patient group; a Phase 3 trial is evaluating whether adding JNJ-9401 to pasritamig improves outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.